Background/Aims: The aim of the present study was to assess the influence of chronic angiotensin-converting enzyme (ACE) inhibitor administration on the development of contrast-induced nephropathy (CIN) in patients undergoing coronary angiography. Methods: A total of 230 patients with renal insufficiency and age ≧65 years were divided into two groups according to prior use of ACE inhibitors (ACE inhibitor group, n = 109; control group, n = 121). CIN was defined as an increase of ≧25% in creatinine over the baseline value within 48 h of angiography. Results: CIN occurred in 17 patients (15.6%) in the ACE inhibitor group and 7 patients (5.8%) in the control group (p = 0.015). Serum creatinine level increased from 1.34 ± 0.20 to 1.53 ± 0.27 mg/dl in the ACE inhibitor group and from 1.33 ± 0.18 to 1.45 ± 0.19 mg/dl in the control group (p < 0.001). Chronic ACE inhibitor administration was a risk indicator of CIN [odds ratio 3.37; 95% confidence interval 1.14–9.94; p = 0.028]. Multi-vessel coronary involvement (p = 0.001), hypoalbuminemia (p = 0.005), diabetes mellitus (p = 0.006), GFR ≤40 ml/min (p = 0.010), and congestive heart failure (p = 0.024) were other risk indicators of CIN. Conclusion: Chronic ACE inhibitor administration is a risk for developing CIN in elderly patients with renal insufficiency.

Keywords:
Angiotensin-converting enzyme inhibitors, Contrast media, Coronary angiography, Elderly, Nephropathy
1.
Detrenis S, Meschi M, Musini S, Savazzi G: Lights and shadows on the pathogenesis of contrast-induced nephropathy: state of the art. Nephrol Dial Transplant 2005;20:1542–1550.
2.
Persson PB, Hansell P, Liss P: Pathophysiology of contrast medium-induced nephropathy. Kidney Int 2005;68:14–22.
3.
McCullough PA, Soman SS: Contrast-induced nephropathy. Crit Care Clin 2005;21:261–280.
4.
Rihal CS, Textor SC, Grill DE, et al: Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation2002;105:2259–2264.
5.
Gami AS, Garovic VD: Contrast nephropathy after coronary angiography. Mayo Clin Proc 2004;79:211–219.
6.
Toprak O, Cirit M, Bayata S, Yesil M: Review of the radiocontrast nephropathy risk profiles and risk stratification. Anadolu Kardiyol Derg 2004;4:331–335.
7.
Mehran R, Aymong ED, Nikolsky E, et al: A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004;44:1393–1399.
8.
Rich MW, Crecelius CA: Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study. Arch Intern Med 1990;150:1237–1242.
9.
Kohli HS, Bhaskaran MC, Muthukumar T, et al: Treatment-related acute renal failure in the elderly: a hospital-based prospective study. Nephrol Dial Transplant 2000;15:212–217.
10.
Toprak O, Bayata S, Tanrısev M: Can we use the ACE inhibitors on prevention of radiocontrast nephropathy? Türkiye Klinikleri J Cardiol 2004;17:375–381.
11.
Gupta RK, Kapoor A, Tewari S, Sinha N, Sharma RK: Captopril for preventing of contrast-induced nephropathy in diabetic patients: a randomized study. Indian Heart J 1999;51:521–526.
12.
Caldicott WJ, Hollenberg NK, Abrams HL: Characteristics of response of renal vascular bed to contrast media. Evidence for vasoconstriction induced by renin-angiotensin system. Invest Radiol 1970;5:539–547.
13.
Toprak O, Cirit M, Bayata S, Yesil M, Aslan LS: The effect of pre-procedural captopril on contrast media induced nephropathy who underwent coronary angiography. Anadolu Kardiyol Derg 2003;3:98–103.
14.
Louis BM, Hoch BS, Hernandez C, et al: Protection from the nephrotoxicity of contrast dye. Ren Fail 1996;18:639–646.
15.
Kini AS, Mitre CA, Kamran M, et al: Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam. Am J Cardiol 2002;89:999–1002.
16.
Brewster UC, Perazella MA: The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med 2004;116:263–272.
17.
Gibbons GH: Vasculoprotective and cardioprotective mechanisms of angiotensin-converting enzyme inhibition: the homeostatic balance between angiotensin II and nitric oxide. Clin Cardiol 1997;20(suppl 2):18–25.
18.
Fleming I, Kohlstedt K, Busse R: New fACEs to the Renin-Angiotensin System. J Appl Physiol 2005;20:91–95.
19.
Munzel T, Keaney JF Jr: Are ACE inhibitors a ‘magic bullet’ against oxidative stress? Circulation 2001;104:1571–1574.
20.
Cheriex EC, Leunissen KM, Janssen JH, Mooy JM, van Hooff JP: Echography of the inferior vena cava is a simple and reliable tool for estimation of ’dryweight’ in haemodialysis patients. Nephrol Dial Transplant 1989;4:563–568.
21.
Parmley WW: Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection. Am J Med 1998;105:S27–S31.
22.
Workman RJ, Shaff MI, Jackson RV, Diggs J, Frazer MG, Briscoe C: Relationship of renal hemodynamic and functional changes following intravascular contrast to the renin-angiotensin system and renal prostacyclin in the dog. Invest Radiol 1983;18:160–166.
23.
Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS: Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 2001;104:1985–1991.
24.
Shaper AG, Wannamethee SG, Whincup PH. Serum albumin and risk of stroke, coronary heart disease, and mortality: the role of cigarette smoking. J Clin Epidemiol 2004;57:195–202.
25.
Chawla LS, Abell L, Mazhari R, et al: Identifying critically ill patients at high risk for developing acute renal failure: a pilot study. Kidney Int 2005;68:2274–2280.
26.
Vuong TD, Braam B, Willekes-Koolschijn N, Boer P, Koomans HA, Joles JA: Hypoalbuminaemia enhances the renal vasoconstrictor effect of lysophosphatidylcholine. Nephrol Dial Transplant 2003;18:1485–1492.
27.
Ni Z, Vaziri ND: Downregulation of nitric oxide synthase in nephrotic syndrome: role of proteinuria. Biochim Biophys Acta 2003;1638:129–137.
28.
Nikolsky E, Mehran R, Lasic Z, et al: Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kidney Int 2005;67:706–713.
29.
Risch L, Blumberg A, Huber AR: Assessment of renal function in renal transplant patients using cystatin C. A comparison to other renal function markers and estimates. Ren Fail 2001;23:439–448.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.